The Hillstream Biopharma Inc (NASDAQ: HILS) stock price surged 22.4% after revealing that it had developed proprietary targeted biologics, Knob Quatrabodies™ (HSB-1940), against PD-1.
eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
On a separate note, the company announced that it had signed collaboration agreements with Minotaur Therapeutics, Inc and a subsidiary of OmniAb, Inc. to advance Picobodies against the novel, unreachable and undruggable epitopes in high-value validated targets starting with PD-1.
Top Broker Recommendation
- XTB UK regulated by the FCA – Read our Review
- Admiral Markets More than 4500 stocks & over 200 ETFs available to invest in – Read our Review
- BlackBull 26,000+ Shares, Options, ETFs, Bonds, and other underlying assets – Read our Review
- eToro Wide range of instruments available to trade – Read our Review
- IG Top-tier regulation – Read our Review
YOUR CAPITAL IS AT RISK. 76% OF RETAIL CFD ACCOUNTS LOSE MONEY
Hillstream Bio said that it would use the technologies licensed from Minotaur and OmniAb to develop and advance biotherapeutics against high-value validated targets.
Picobodies are antibody “knob” domains comprised of the cysteine-rich ultralong complementary determining region (CDR) H3 sequences of 30-40 amino acids. These can potentially access challenging epitopes better than full-size antibodies can.
By combining Quatramers with their long half-life coated with a PD-1 Picobody™ to create HSB-1940, Hillstream believes it could more efficiently target novel epitopes with greater binding affinity than approved biologics. In addition, targeting PD-1 is a step toward enabling Hillstream to enter the rapidly growing Immuno-oncology (IO) therapeutics market with additional IO targets after PD-L1.
Dr Vaughn Smider, Minotaur’s Founder and CEO, stated: “We are excited to contribute our expertise to help in combining OmniAb’s OmniTaur-derived ultralong CDR H3 antibody fragments and Hillstream’s tumor-targeting Quatramers to discover and develop novel next-generation targeted cancer therapeutics.”
Randy Milby, Hillstream Biopharma’s CEO, stated: “The Picobodies which OmniAb brings to this collaboration combined with our Quatramers to create a novel and disruptive Knob Quatramer platform will be a great addition to our portfolio starting with HSB-1940. We are doubly excited that Dr Vaughn Smider, a pioneer in discovering, engineering and understanding these unique proteins, will lead Minotaur’s services. The Quatramer is a key Hillstream platform which is now poised to create novel therapeutics using “smart carriers” with multiple approaches for enhancing targeted cancer immunotherapy.”
*This is not investment advice.
Hillstream Biopharma (HILS) stock price.
The Hillstream Biopharma stock price surged 22.36% to trade at $0.4800, rising from Wednesday’s closing price of $0.3923.
eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
